Source disclosure: February 20, 2026
Modalis Therapeutics Corporation [4883.T]
TOKYO, Feb 20 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) announced plans to reduce its capital funds and transfer surplus reserves at its upcoming annual shareholders' meeting scheduled for March 26, 2026. The move aims to offset a deficit of ¥2.249 billion reported at the end of the fiscal year and enhance the company's financial health while maintaining flexibility for future capital policies.
Under the plan, the company intends to decrease its capital fund by ¥1.125 billion and its reserve fund by ¥1.125 billion. Both reductions will be transferred to additional capital surplus. Additionally, pursuant to the Companies Act, the company will reallocate the increased additional capital surplus to retained earnings, aiming to cover the deficit.
The effective date for these changes is set for May 15, 2026. This adjustment will not affect the number of shares held by shareholders or alter the company’s net assets per share. The company expects no impact on its operating performance from this action, which requires approval at the upcoming shareholder meeting.
AI-translated content. 🟢 Confidence: High See terms • Original filing